Hemagen Diagnostics (Hemagen Diagnostics) Additional Paid-In Capital : $23.13 Mil(As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Additional Paid-In Capital?

Hemagen Diagnostics's quarterly additional paid-in capital increased from Mar. 2012 ($23.09 Mil) to Jun. 2012 ($23.11 Mil) and increased from Jun. 2012 ($23.11 Mil) to Sep. 2012 ($23.13 Mil).

Hemagen Diagnostics's annual additional paid-in capital increased from Sep. 2010 ($22.96 Mil) to Sep. 2011 ($23.04 Mil) and increased from Sep. 2011 ($23.04 Mil) to Sep. 2012 ($23.13 Mil).

Hemagen Diagnostics Additional Paid-In Capital Historical Data

The historical data trend for Hemagen Diagnostics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Additional Paid-In Capital Chart

Hemagen Diagnostics Annual Data

Trend

Sep03

Sep04

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Additional Paid-In Capital

Get a 7-Day Free Trial

22.87

22.92

22.96

23.04

23.13

Hemagen Diagnostics Quarterly Data
	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12
Additional Paid-In Capital	Get a 7-Day Free Trial															23.04	23.06	23.09	23.11	23.13

Hemagen Diagnostics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Hemagen Diagnostics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

9033 Red Branch Road, Columbia, MD, USA, 21045

Website

http://www.hemagen.com

Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.

Executives

Howard F Curd

director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines